Chronic Myeloid Leukemia Treatment Market, by Drug Type (Tyrosine Kinase Inhibitors, Antimetabolites, and Others), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Chronic myeloid leukemia (CML) is a cancer that initiates in the blood-forming cells of the bone marrow and enters the blood. It increases the number of white blood cells in the blood. Chronic myeloid leukemia is also known as chronic myelogenous leukemia. Chronic myeloid leukemia (CML) occurs mostly in adults, and rarely in children. Chronic myeloid leukemia (CML) is detected after the blood test is performed.

Chronic myeloid leukemia symptoms includes:

• Bone pain
• Easy bleeding
• Fever
• Weight loss
• Excessive sweating during sleep

Market Dynamics

Increasing number of drug launches by market key players is expected to drive the growth of global chronic myeloid leukemia treatment market during the forecast period. For instance, in September 2017, Mylan N.V., a pharmaceutical company, announced the launch of Imatinib Mesylate tablets, 100 mg and 400 mg, a generic version of Novartis's Gleevec Tablets. Moreover, Mesylate tablets are approved by US Food and Drug Administration for the treatment of acute lymphoblastic leukemia, chronic eosinophilic leukemia or hypereosinophilic syndrome, chronic myelogenous leukemia, and others.

Increasing number of inorganic growth strategies such as strategic collaboration by market key players is expected to drive the growth of global chronic myeloid leukemia treatment market. For instance, in July 2021, Innovent Biologics, Inc., a biopharmaceutical company, announced strategic collaboration with Ascentage Pharma, a biopharmaceutical company. Moreover, this collaboration includes the joint clinical development and commercialization of HQP1351 (olverembatinib), a third-generation BCR-ABL inhibitor in China. Olverembatinib is indicated for the treatment of adult patients with tyrosine kinase inhibitor (TKI)-resistant chronic phase chronic myeloid leukemia (CML-CP) or accelerated-phase CML (CML-AP).

Key features of the study:

• This report provides an in-depth analysis of global chronic myeloid leukemia treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players

• It profiles leading players in the global chronic myeloid leukemia treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.

• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Pfizer, Inc., Takeda Pharmaceutical Company Limited, Innovent Biologics, Inc., Viatris Inc. (Mylan N.V.), Lupin, IL-YANG PHARM CO. LTD., Million Health Pharmaceuticals, and Celon Labs

• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics

• The global chronic myeloid leukemia treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.

• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global chronic myeloid leukemia treatment market

Detailed Segmentation:

• Global Chronic Myeloid Leukemia Treatment Market, By Drug Type:
• Tyrosine Kinase Inhibitors
  • Imatinib (Gleevac)
  • Dasatinib (Sprycel)
  • Nilotinib (Tasigna)
  • Bosutinib (Bosulif)
  • Ponatinib (Iclusig)
  • Asciminib (Scemblix)
  • Others
• Antimetabolites
• Others
• Global Chronic Myeloid Leukemia Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Chronic Myeloid Leukemia Treatment Market, By Region:
• North America
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • U.S.
  • Canada
• Latin America
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • Middle East
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
• By Drug Type:
  • Tyrosine Kinase Inhibitors
    • Imatinib (Gleevac)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig)
    • Asciminib (Scemblix)
    • Others
  • Antimetabolites
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
• Teva Pharmaceutical Industries Ltd.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bristol-Myers Squibb Company
• Pfizer, Inc.
• Takeda Pharmaceutical Company Limited
• Innovent Biologics, Inc.
• Viatris Inc. (Mylan N.V.)
• Lupin
• IL-YANG PHARM CO. LTD.
• Million Health Pharmaceuticals
• Celon Labs

"*" marked represents similar segmentation in other categories in the respective section.